Dena A. Jerjees
The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways
Jerjees, Dena A.; Negm, Ola H.; Alabdullah, M. Layth; Mirza, Sameer; Alkaabi, Methaq; Hameed, Mohamed R.; Abduljabbar, Rezvan; Muftah, Abir; Nolan, Chris C.; Green, Andrew R.; Tighe, Patrick J.; Band, Vimla; Ellis, Ian O.; Rakha, Emad A.
Authors
Dr Ola Negm ola.negm@nottingham.ac.uk
ASSISTANT PROFESSOR
M. Layth Alabdullah
Sameer Mirza
Methaq Alkaabi
Mohamed R. Hameed
Rezvan Abduljabbar
Abir Muftah
Chris C. Nolan
Dr Andy Green ANDREW.GREEN@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Professor PATRICK TIGHE paddy.tighe@nottingham.ac.uk
PROFESSOR OF MOLECULAR IMMUNOLOGY
Vimla Band
Ian O. Ellis
Professor EMAD RAKHA Emad.Rakha@nottingham.ac.uk
PROFESSOR OF BREAST CANCER PATHOLOGY
Abstract
The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it with key clinicopathological and molecular features of BC especially to proteins related to oestrogen receptor (ER) and HER2 pathways in different BC classes. Moreover, mTORC1 expression was assessed in 6 BC cell lines including ER+ and ER− cell lines with and without HER2 transfection. Immunohistochemistry was used to assess the expression of phospho (p) mTORC1 in a large (n = 1300) annotated BC series prepared as tissue microarray. Reverse phase protein array (RPPA) was used to assess its expression in the different BC cell lines. The expression of p-mTORC1 was cytoplasmic with moderate/high expression noted in 44 % of BC. p-mTORC1 expression was associated with clinicopathological variables characteristic of good prognosis. Positive correlation with ER, ER-related proteins AKT, PI3K and luminal differentiation markers were observed in the whole series and in the ER+HER2− subgroup. Association with HER2 was mainly observed in the ER-negative class. RPPA indicated that p-mTORC1 expression was mainly related to ER expression and with better outcome in the Akt positive tumours. p-mTORC1 is associated with good prognostic features. Its expression is related to ER and ER related proteins in addition to AKT and PI3K. Its relation with HER2 expression is mainly seen in the absence of ER expression.
Citation
Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Alkaabi, M., Hameed, M. R., Abduljabbar, R., Muftah, A., Nolan, C. C., Green, A. R., Tighe, P. J., Band, V., Ellis, I. O., & Rakha, E. A. (2015). The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 150(1), 91-103. https://doi.org/10.1007/s10549-015-3308-4
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 9, 2015 |
Online Publication Date | Feb 21, 2015 |
Publication Date | 2015-02 |
Deposit Date | Oct 17, 2018 |
Journal | Breast Cancer Research and Treatment |
Print ISSN | 0167-6806 |
Electronic ISSN | 1573-7217 |
Publisher | Springer Verlag |
Peer Reviewed | Peer Reviewed |
Volume | 150 |
Issue | 1 |
Pages | 91-103 |
DOI | https://doi.org/10.1007/s10549-015-3308-4 |
Public URL | https://nottingham-repository.worktribe.com/output/1171514 |
Publisher URL | https://link.springer.com/article/10.1007%2Fs10549-015-3308-4 |
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search